Activating mutations of the interleukin-7 receptor (IL7R) occur in approximately 10% of patients with T cell acute lymphoblastic leukaemia (T-ALL). Most mutations generate a cysteine at the transmembrane domain leading to receptor homodimerization through disulfide bond formation and ligand-independent activation of STAT5. We hypothesized that the reducing agent N-acetylcysteine (NAC), a well-tolerated drug used widely in clinical practice to treat acetaminophen overdose, would reduce disulfide bond formation, and inhibit mutant IL7R-mediated oncogenic signalling. We found that treatment with NAC disrupted IL7R homodimerization in IL7R-mutant DND-41 cells as assessed by non-reducing Western blot, as well as in a luciferase complementation assay. NAC led to STAT5 dephosphorylation and cell apoptosis at clinically achievable concentrations in DND-41 cells, and Ba/F3 cells transformed by an IL7R-mutant construct containing a cysteine insertion. The apoptotic effects of NAC could be rescued in part by a constitutively active allele of STAT5. Despite using doses lower than those tolerated in humans, NAC treatment significantly inhibited the progression of human DND-41 cells engrafted in immunodeficient mice. Thus, targeting leukaemogenic IL7R homodimerization with NAC offers a potentially effective and feasible therapeutic strategy that warrants testing in patients with T-ALL.
Coordinated signalling through the JAK and STAT pathways is essential for normal lymphopoiesis (Higuchi et al, 1997; Igaz et al, 2001 ). This dependence is exemplified by the development of severe combined immunodeficiency when integral components of this pathway, including interleukin-7 receptor alpha (IL7R), are inactivated through loss-of-function genetic lesions (Kalman et al, 2004) . Conversely, constitutive activation of JAK-STAT signalling has been implicated in the development of acute lymphoblastic leukaemia (ALL), with activating mutations in JAK1, JAK2, JAK3, and more recently STAT5B and TYK2, all identified in T-ALL (Flex et al, 2008; Zhang et al, 2012; Kontro et al, 2014; Sanda et al, 2013) .
Several groups recently reported the presence of somatically acquired activating IL7R mutations occurring in approximately 10% of T-ALL cases (Shochat et al, 2011; Zenatti et al, 2011; Zhang et al, 2012) . The vast majority of such mutations are short in-frame insertions that result in the introduction of a novel cysteine just extracellular to the transmembrane domain. These unpaired cysteine residues result in inter-molecular disulfide bond formation leading to ligandindependent IL7R homodimerization, and constitutive JAK1 activation with phosphorylation and activation of STAT5 (Shochat et al, 2011; Zenatti et al, 2011; Zhang et al, 2012) . Furthermore, inhibition of JAK-STAT signalling results in apoptosis of IL7R-mutant cells, suggesting that these tumours depend on this pathway for survival (Shochat et al, 2011; Zenatti et al, 2011; Porcu et al, 2012; Zhang et al, 2012) .
We hypothesized that leukaemogenic activation of this pathway by cysteine mutations in IL7R could be blocked with the reducing agent N-acetylcysteine (NAC), which is able to reduce disulfide bond formation in vitro and in vivo (Cartwright et al, 1977; Chen et al, 2011) . NAC is an approved drug that has been used extensively and safely in clinical practice as an antidote for acetaminophen overdose for over three decades (Peterson & Rumack, 1977; Smilkstein et al, 1988) . Here we use biochemical, genetic and in vivo studies to show that NAC treatment inhibits mutant IL7R-mediated oncogenic signalling by disrupting disulfide bond formation, potentially offering an effective, affordable and well-tolerated therapeutic strategy for T-ALL patients with IL7R cysteine insertions.
Materials and methods
Cell culture, IL7R sequencing and NAC treatment in vitro T-ALL cell lines were maintained as previously described (Sanda et al, 2013) . Exon 6 of IL7R was Sanger sequenced from T-ALL cell lines using the published protocol (Shochat et al, 2011) . For drug assays, cells were grown at a density of 1 9 10 5 /ml in 96-well format and treated with NAC (SigmaAldrich, St. Louis, MO, USA). Due to the acidity of NAC in culture, both control and NAC treated wells were additionally buffered with 20 mmol/l HEPES (Invitrogen, Grand Island, NY, USA).
Retroviral transductions
The pMSCV-IL7R-243insPPCL-IRES-GFP and pMSCV-IL7R-V253G-IRES-GFP were created by site directed mutagenesis from pMSCV-IL7R-IRES-GFP wild-type vector (Stratagene/ Agilent, Santa Clara, CA, USA) (Shochat et al, 2011) . pMSCV-BCR-ABL-puro has been previously described . The pMX-Stat5b1*6-IRES-GFP constitutively active murine STAT5B mutant (aStat5b) and control pMX-IRES-GFP retroviral vectors were kind gifts from Professor Toshio Kitamura (University of Tokyo, Tokyo, Japan), and were used in DND-41 rescue experiments (Onishi et al, 1998) . The pMSCV-cS5 F -IRES-eGFP encoding a constitutively active murine STAT5A mutant (S710F=cS5) and control pMSCV-IRES-eGFP were cloned and validated previously (Moriggl et al, 2005) . These constructs were used in the Ba/F3 rescue experiments because their high GFP expression allowed sorting of a Ba/F3-IL7R-PPCL population co-expressing cS5. The generation of retroviral supernatants, viral transductions and cell selection have been described previously (Sanda et al, 2013) .
Western blots
Immunoblotting was carried out with the following antibodies: anti-IL7Ra (clone-40131; R&D Systems, Minneapolis, MN, USA) and anti-pY-STAT5 (Y694) (Cell Signaling Technology, Danvers, MA, USA), both diluted 1 in 1000; anti-b-actin (ACTB); Sigma-Aldrich) diluted 1 in 5000 and secondary horseradish peroxidase (HRP)-linked antibody to mouse or rabbit (Cell Signaling Technology) diluted 1 in 10 000.
Cell viability and apoptosis assays
Cell viability in vitro was determined at 48 h after the initiation of treatment with NAC using the Cell Titer Glo assay (Promega, Madison, WI, USA). For Annexin V staining, cells were washed twice in phosphate-buffered saline (PBS) at 24 h after drug treatment, labelled with Annexin V fluorescein isothiocyanate (FITC) antibody (BD Pharmingen, San Jose, CA, USA) according to the manufacturer's recommendations and assessed by flow cytometry.
Luciferase complementation assay
The luciferase complementation assay was performed according to the protocol of Cassonnet et al (2011) . Wild-type and mutant (p.L242_L243ins PPCL) IL7R sequences were amplified from MSCV-IL7R-IRES-GFP plasmid templates (Shochat et al, 2011) Xenograft model 1 9 10 6 luciferase-expressing DND-41 cells were injected into the tail vein of 7-week-old female NOD-SCID-IL2Rcg null (NSG) mice (The Jackson Laboratory, Bar Harbor, ME, USA). Tumour burden was assessed by bioluminescence imaging (BLI) using an IVIS Spectrum system (Caliper Life Sciences, Santa Clara, CA, USA), every 3-5 d until leukaemia was established, generally 2-3 weeks after intravenous injection, at which time NAC therapy was initiated. For each BLI time point, cancer bioluminescence was visualized by intraperitoneal (IP) injection of d-luciferin (Promega) in PBS at 75 mg/kg. In the pilot study, NAC-treated mice received the drug (Sigma-Aldrich) both in drinking water (10 mg/ml, supplemented with 45 mg/ml dextrose for palatability) and by IP injection 1 g/kg bid (twice daily) for 7 d, because continuous intravenous (IV) administration is not feasible in mice and osmotic administration using implanted pumps is precluded by the need to achieve micromolar concentrations.
In the follow-up experiment, mice either received NAC by IP injection (1 g/kg) bid, or IP injections of PBS. For IP injections, NAC was made up with water and brought to pH = 5 with NaOH and filter-sterilized. Mice treated with this approach for 19 d displayed no detectable toxicity or weight loss upon daily monitoring. Femurs were fixed in 10% formalin, sectioned, paraffin-embedded and stained with anti-human-CD45 antibody (Clone 2B11 + PD7/26, diluted 1 in 50; Dako/Agilent, Santa Clara, CA, USA). Stained slides were photographed using an Olympus BX41 microscope and Q-colour5 digital camera (Olympus, Center Valley, PA, USA) and staining scores were calculated using APERIO software (Leica, Newcastle, UK).
Statistical analyses
Dose-response curves were fitted using least squares (ordinary) fit as log (inhibitor) versus response using GRAPHPAD PRISM software (GraphPad Software, La Jolla, CA, USA). Differential sensitivities were calculated by non-linear regression. Two-tailed Student's t-test was used to calculate statistical differences between continuous variables, with P < 0Á05 considered as statistically significant.
Results
To identify a cell model of mutant IL7R signalling, we first sequenced exon 6 of IL7R in 21 T-ALL cell lines. We identified one somatic mutation; a 12 bp insertion in DND-41 cells resulting in a 4-amino-acid insertion (p.L242_L243ins-LSRC), as described previously (Table I) (Porcu et al, 2012) . Modelling the insertion on the crystal structure of IL7R using the PYMOL software (Schrodiner, New York, NY, USA) predicted that it would reside just extracellular to the transmembrane domain and form homodimers through disulfide bond formation with the unpaired cysteine from the other mutant IL7R molecules ( Fig 1A) (McElroy et al, 2009 (McElroy et al, , 2012 . Of note, we had previously detected particularly high levels of phospho-STAT5 (pSTAT5) in this cell line by Western blotting (see fig S3 in Sanda et al, 2013] ) consistent with its activation by mutant IL7R signalling.
We next tested the effects of NAC on the viability of cells from a panel of ten T-ALL cell lines over a broad dose range. Cell lines could be broadly categorized as resistant [MOLT-16, RPMI-8402; 50% inhibitory concentration (IC50) >300 lmol/l], moderately sensitive (for example, KOPT-K1 and SUP-T13; IC50 257 lmol/l and 141 lmol/l respectively) and sensitive (for example, DND-41 and CCRF-CEM; IC50 74 lmol/l and 62 lmol/l respectively; Fig 1B and Table I ). IL7R-mutant DND-41 cells were among the most sensitive of the cell lines tested. We hypothesized that the efficacy of NAC in DND-41 cells was mediated, at least in part, through disruption of mutant IL7R homodimers, while the sensitivity identified in cell lines such as CCRF-CEM was probably mediated through disruption of disulfide bonds in other cell surface receptors required for cell survival. The reduction in cell viability in DND-41 cells occurred through apoptosis as determined by Annexin V staining (Fig 1C) .
Given that we were able to find only a single T-ALL cell line harbouring an IL7R mutation, we recapitulated oncogenic IL7R signalling in Ba/F3 cells using two different IL7R mutations previously described in patients: IL7R-ins243PPCL and IL7R-V253G (Shochat et al, 2011) . The IL7R-ins243PPCL mutation is similar to the DND-41 IL7R-243insLSRC mutation in both its insertion position and size, and is predicted to lead to receptor homodimerization through disulfide bond formation from the novel cysteine. By contrast, the IL7R-V253G resides deep within the membrane, and mediates constitutive STAT5 activation through an alternative allosteric mechanism that does not involve the formation of disulfide bonds (Shochat et al, 2014) . Both mutations transformed Ba/ F3 cells to IL3-independence. In support of our hypothesis, Ba/F3 cells transformed by IL7R-ins243PPCL were significantly more sensitive to NAC than Ba/F3 cells transformed by IL7R-V253G or BCR-ABL1 (P < 0Á001, Fig 1D) .
Western blotting of endogenous IL7R in DND-41 cells under non-reducing conditions demonstrated disruption of the IL7R homodimer at the same doses as those required to induce apoptosis in vitro, with associated loss of STAT5 phosphorylation (Fig 2A) . We also tested IL7R homodimerization quantitatively in a luciferase complementation assay in HEK-293T cells using constructs encoding the N-or C-terminus of Gaussia princeps luciferase fused to the intracellular domain of IL7R, such that functional luciferase activity occurs on IL7R protein-protein interaction. When expressed individually, the N-or C-terminal luciferase constructs alone were unable to generate a luciferase signal (Fig 2B) . However, a robust luciferase signal was obtained when the N-and C-terminal IL7R constructs were expressed concurrently, which was significantly stronger (P < 0Á001) with IL7R-PPCL than the wild-type (WT) IL7R constructs (notably, WT-IL7R has previously been shown to homodimerize in an inactive configuration through an N-terminal hydrogen bond) (McElroy et al, 2012) . NAC had no effect on WT IL7R constructs but, consistent with what we had observed through Western blotting, treatment with NAC significantly inhibited homodimerization of IL7R-PPCL (P < 0Á001, Fig 2B) . In this assay, NAC had the same effect as b-mercaptoethanol (BME), a reducing agent commonly used in vitro, which has been previously shown to inhibit mutant IL7R signalling in vitro (Zenatti et al, 2011) . However, given the reported toxicity of BME in vivo compared to the excellent tolerability of NAC, we chose not to pursue BME as a therapeutic agent for T-ALL (White et al, 1973) .
To determine whether loss of viability in DND-41 cells from NAC treatment was mediated predominantly through inhibition of STAT5 signalling, we retrovirally transduced DND-41 cells with a constitutively active STAT5 construct (termed aStat5b) (Onishi et al, 1998) , such that signalling downstream of STAT5 was no longer dependent on mutant IL7R homodimerization. Consistent with our proposed mechanism, DND-41-aStat5 cells were significantly more resistant to NAC treatment than control transduced DND-41 cells (P < 0Á001, Fig 2C) . Similarly, when IL7R-PPCL transformed Ba/F3 cells were engineered to co-express constitutively active STAT5 (aStat5a) (Moriggl et al, 2005) , they demonstrated increasing resistance to NAC therapy (P < 0Á05, Fig 2D) , suggesting the effects of NAC on cell viability were mediated at least in part through STAT5 signalling. The lack of a complete rescue may be attributable to the fact that the IL7R pathway also activates PI3K-AKT signalling in a STAT5 independent fashion (Dadi & Roifman, 1993; Sharfe et al, 1995; Barata et al, 2004; Silva et al, 2011) .
Given that NAC concentrations of 150-300 lmol/l are required to kill DND-41 cells in vitro, we examined published pharmacokinetic studies to determine if therapeutic levels of NAC are potentially achievable in human subjects. A single oral dose of 600 mg of NAC results in plasma levels of approximately 30-60 lmol/l (De Caro et al, 1989; Holdiness, 1991; Chen et al, 2007) , with pharmacokinetics influenced by poor bioavailability, extensive first-pass metabolism and short half-life (Table II) (Borgstrom et al, 1986; Hong et al, 2005) . Consequently, a widely adopted approach of treating acetaminophen overdose is continuous IV infusion of NAC (Smilkstein et al, 1991) , which produces steadystate NAC plasma levels up to 930 lmol/l (Table II) , well within the therapeutic range required to induce apoptosis of DND-41 cells (Borgstrom et al, 1986; Brown et al, 2004; Chen et al, 2007) . This suggests that the therapeutic concentrations of NAC required to treat IL7R-mutant leukaemias are readily achievable in humans.
We then tested the efficacy of NAC in vivo using a murine xenograft model. NOD-SCID-IL2Rcg null (NSG) mice were injected with 1 9 10 6 luciferase-expressing IL7R-mutant DND-41 cells and were treated with NAC once tumour 
À, no pYSTAT5 detectable; +, detectable pYSTAT5; ++, strong pYSTAT5; IC 50 , 50% inhibitory concentration; WT, wild-type. *As determined by Western blot. Data from (Sanda et al, 2013) .
engraftment was established by BLI. In an attempt to achieve therapeutic levels of NAC, and limited by the difficulty in administering continuous IV infusions to NSG mice due to their small size, we opted to administer NAC both in drinking water (10 mg/ml) and by IP injection (1 g/kg bid) in our initial pilot study (n = 4 per group), starting after leukaemia was established, generally 2-3 weeks after intravenous injection of leukaemic cells. After 7 d of treatment, we observed striking responses in two of four mice, with few if any detectable leukaemic cells by BLI, as compared to widespread disease in all four control treated animals ( Fig 3A) . However, one of the mice died of dehydration because of refusal to drink the NAC-containing drinking water, which has the foul odor of rotten eggs.
To avoid the difficulty with oral administration, we gave mice free access to drinking water and administered NAC by IP injection 1 g/kg twice per day (Fig 3B) . Despite the suboptimal pharmacokinetics of IP NAC (in vivo half-life in mice, 9-11 min) (Neuwelt et al, 2004) , NAC treatment nonetheless significantly delayed tumour progression in this model (Fig 3C,D) : mean bioluminescence on day 19 was 13Á9 9 10 9 for control versus 7Á75 9 10 9 /photons (ph)/s/ cm 2 /steradian (sr) for NAC-treated animals (P < 0Á001; n = 8 in each group). We confirmed these findings by analysing bone marrow biopsies of mice for the presence of human leukaemia cells, as measured by immunohistochemistry against human CD45 (Fig 3E) . We consistently found a marked reduction of human T-ALL burden in mice treated with NAC as compared to control animals ( Fig 3F , P < 0Á005).
Discussion Peterson and Rumack (1997) initially reported the clinical use of NAC to reverse the severe hepatic toxicity associated with acetaminophen overdose. Since then, this antidote has saved countless lives and to this day remains the mainstay of effective treatment for this indication (Ferner et al, 2011) . Given that acetaminophen overdose is the commonest form of poisoning worldwide, with over 50 000 cases per annum in the USA alone, the experience of using NAC in the clinic is extensive (Nourjah et al, 2006) . Despite the remarkably high steady-state plasma concentrations achievable on standard treatment protocols, it has an exceptionally favourable tolerability profile. As predicted based on the known reducing properties of NAC, it was able to disrupt cysteine-bond-mediated homodimers of mutant IL7R, resulting in reduced pSTAT5 expression and the induction of apoptosis in IL7R mutant DND-41 human T-ALL cells. Unfortunately, we found only a single human T-ALL cell line that harbours an IL7R mutation. For this reason, we also analysed Ba/F3 cells immortalized with a cysteine-mutated activated IL7R, and these cells also responded to treatment with NAC. We also observed a NAC also showed effects on cell viability in IL7R-WT T-ALL cell lines, such as SUP-T13, when the cells were treated at high concentrations. We are not sure of the mechanism of activity, although one could surmize that intramolecular cysteine bonds in key cellular proteins might also be required for T-ALL cell viability. For example, many cell surface receptors contain reactive cysteines involved in the formation of intra-and inter-molecular disulfide bond formation (Metcalfe et al, 2011) , the reduction of which are likely to have consequences on receptor configuration and affect 'outside-in' signalling; increased dependency on such signals in leukaemic cells compared to normal cells may offer the therapeutic window predicted from our data. Further studies will be required to investigate the cytotoxic effects of NAC in T-ALLs lacking IL7R mutations. The fact that patients can tolerate continuous NAC infusions for over 24 h, where steady state plasma levels are >300 lmol/l, without undergoing catastrophic organ failure, suggests that this leukaemia- A luciferase complementation assay to quantify IL7R homodimerization. The assay is based on the principle that expression of two separate inactive fragments of luciferase will produce a functionally active luciferase protein only after significant protein-protein interaction (Cassonnet et al, 2011) . Either the N-or C-terminal fragments of luciferase (LUC) were fused to the intracellular domain of wild-type and mutant IL7R (ins PPCL) constructs and expressed in HEK-293T cells for 48 h, treated with or without NAC or b-mercaptoethanol (BME 2 mmol/l) for 90 min, before measurement of Gaussia princeps luciferase activity. Of note, homodimerization of wild-type IL7R has been previously described by crystallography, where the IL7R homodimers are held together by an intermolecular hydrogen bond at the N-terminus, maintaining the dimer in a non-active conformation (McElroy et al, 2012) . (C) Expression of a constitutively active mutant of Stat5b partially rescues DND-41 cells from apoptosis induced by NAC. DND-41 cells were transduced with either a control pMX-IRES-GFP or pMX-Stat5B*-IRES-GFP retroviral vector encoding a constitutively active Stat5b construct, selected by fluorescence-activated cell sorting (FACS) and then treated with NAC for 48 h before cell viability was measured by the Cell Titer Glo assay. The P value was calculated using non-linear regression. (D) Ba/F3 cells transformed by IL7R-insPPCL were infected with retroviral vectors expressing a constitutively active murine Stat5a mutant (S710F) or control pMSCV-IRES-eGFP. Cells were sorted by FACS for high GFP expression, then treated with NAC for 48 h before cell viability was measured by the Cell Titer Glo assay. The P value was calculated using non-linear regression. specific cytotoxicity may prove clinically useful in a subset of T-ALL cases that lack IL7R mutations. Other mutations leading to aberrant disulfide bond formation have been shown to activate different oncogenic receptors in several other cancers -F232C mutation of CRLF2 in B-ALL (Hertzberg et al, 2010; Yoda et al, 2010) , RET mutations in thyroid cancers (Asai et al, 1995; Santoro et al, 1995) and HER2 R896C mutation in breast cancer (Bose et al, 2013) -also suggesting that NAC may have application beyond IL7R mutant T-ALL.
One limitation of our study was the inability to adequately dose NSG mice to levels that are comparable to those that are achievable in humans. The most striking responses occurred in mice that were treated with both oral and IP NAC in our pilot study, suggesting that efficacy was dose-dependent, but oral NAC was repulsive to mice and several mice became dehydrated. With an in vivo half-life of NAC in mice of approximately 10 min (Neuwelt et al, 2004) , a continuous IV infusion schedule would have been optimal, but we were technically unable to deliver the drug by this route in such small animals. Nonetheless, we observed significant responses, particularly with respect to leukaemic infiltration of the bone marrow.
Given that optimal and safe dosing schedules to achieve high micromolar plasma concentrations are well-established in humans, our findings suggest that NAC use in IL7R- T-ALL could afford a safe and effective new therapeutic strategy warranting testing in clinical trials. Lastly, it is worth noting that 11 of the 12 US Food and Drug Administration (FDA)-approved cancer drugs in 2012 cost over $100 000 per annum (Experts in Chronic Myeloid Leukemia, 2013) . In the UK, a 2-g ampoule of NAC for IV use costs £1Á96 (equivalent to approximately $3Á20), meaning that a 24-h-infusion on a typical NAC protocol for a 70 kg adult for acetaminophen overdose costs £21Á56 (c. $34Á50). Given the fact that NAC is well tolerated in clinical use by continuous infusion, we recommend that it be evaluated in clinical trials as an approach to targeted therapy for a subset of T-ALL patients, the economical implications of which may be particularly relevant to healthcare in the developing world.
